Other
Heart
1
Pipeline Programs↗
9
Active Trials↗
20
Companies Involved↗
Heart is an early-stage landscape with 1 program across 20 companies. The most active players are AstraZeneca, Eli Lilly, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
77
clinical trials
Completed52 · 68%
Unknown status7 · 9%
Terminated6 · 8%
Active, not recruiting3 · 4%
Withdrawn3 · 4%
Not yet recruiting3 · 4%
Other3 · 4%
Clinical Trials
Trial Activity
77 trials
Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study
Not yet recruiting·RRutgers, The State University of New Jersey·Preclinical·NCT07549334·1,000 enrolled
Executive Function Intervention for Children With Complex Congenital Heart Disease: A Randomised Control Study
Not yet recruiting·—·Preclinical·NCT07692958·160 enrolled
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00481728·28 enrolled
Cardioplegic Protection of the Heart
Completed·—·Phase 4·NCT07386990·40 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)